Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

810 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease.
Schmidt A, Anton A, Shapiro J, Wong S, Azad A, Kwan E, Spain L, Muthusamy A, Torres J, Parente P, Parnis F, Goh J, Joshua AM, Pook D, Gibbs P, Tran B, Weickhardt A. Schmidt A, et al. Among authors: anton a. Asia Pac J Clin Oncol. 2021 Feb;17(1):36-42. doi: 10.1111/ajco.13447. Epub 2020 Sep 24. Asia Pac J Clin Oncol. 2021. PMID: 32970925
Use of prostate-specific membrane antigen positron-emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer.
Anton A, Kamel Hasan O, Ballok Z, Bowden P, Costello AJ, Harewood L, Corcoran NM, Dundee P, Peters JS, Lawrentschuk N, Troy A, Webb D, Chan Y, See A, Siva S, Murphy D, Hofman MS, Tran B. Anton A, et al. BJU Int. 2020 Oct;126(4):433-435. doi: 10.1111/bju.15151. Epub 2020 Aug 4. BJU Int. 2020. PMID: 32579772 No abstract available.
Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.
Anton A, Wong S, Shapiro J, Weickhardt A, Azad A, Kwan EM, Spain L, Gunjur A, Torres J, Parente P, Parnis F, Goh J, Semira MC, Gibbs P, Tran B, Pezaro C. Anton A, et al. Eur J Cancer. 2021 Nov;157:485-492. doi: 10.1016/j.ejca.2021.06.005. Epub 2021 Jul 31. Eur J Cancer. 2021. PMID: 34344533
Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial.
Kwan EM, Spain L, Anton A, Gan CL, Garrett L, Chang D, Liow E, Bennett C, Zheng T, Yu J, Dai C, Du P, Jia S, Fettke H, Abou-Seif C, Kothari G, Shaw M, Parente P, Pezaro C, Tran B, Siva S, Azad AA. Kwan EM, et al. Among authors: anton a. Eur Urol. 2022 Mar;81(3):253-262. doi: 10.1016/j.eururo.2021.08.011. Epub 2021 Sep 4. Eur Urol. 2022. PMID: 34493414 Clinical Trial.
Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer.
Kelly R, Anton A, Wong S, Shapiro J, Weickhardt A, Azad A, Kwan EM, Spain L, Muthusamy A, Torres J, Parente P, Parnis F, Goh J, Joshua A, Pook D, Baenziger O, Gibbs P, Tran B. Kelly R, et al. Among authors: anton a. BJU Int. 2021 Oct;128 Suppl 1:18-26. doi: 10.1111/bju.15364. BJU Int. 2021. PMID: 34622543
810 results